Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $78.6154.

A number of brokerages have recently issued reports on TEM. HC Wainwright increased their target price on Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, March 9th. JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Wall Street Zen lowered Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Mizuho began coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective for the company.

Tempus AI Stock Down 4.2%

Shares of TEM opened at $46.76 on Thursday. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. The company has a 50-day moving average price of $56.13 and a two-hundred day moving average price of $70.16. The stock has a market cap of $8.36 billion, a price-to-earnings ratio of -33.16 and a beta of 5.29. Tempus AI has a 12 month low of $36.22 and a 12 month high of $104.32.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $58.87, for a total transaction of $9,787,137.50. Following the completion of the transaction, the chief executive officer directly owned 8,908,283 shares of the company’s stock, valued at $524,430,620.21. This trade represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the transaction, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 402,591 shares of company stock worth $24,868,936 over the last ninety days. Company insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. increased its position in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the period. Global Retirement Partners LLC lifted its position in Tempus AI by 29.5% during the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after purchasing an additional 167 shares during the period. US Bancorp DE boosted its stake in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after purchasing an additional 176 shares during the last quarter. Legacy Bridge LLC boosted its stake in shares of Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after purchasing an additional 193 shares during the last quarter. Finally, Truist Financial Corp grew its position in shares of Tempus AI by 5.8% during the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after buying an additional 194 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.